Given the negative panel vote today for Xarelto in ACS, JNJ looks pretty smart for submitting a separate NDA for Xarelto in the PCI sub-indication of ACS (#msg-75391993).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”